OneSource Specialty Pharma Ltd

- OneSource Specialty Pharma Limited is investing over $100 million over the next couple of years to expand capacity and capabilities. - They are consciously balancing leverage and access to funds on attractive terms with internal accruals and customer participation. - The company has significantly reduced high-cost debt, cutting it by almost 50% by the end of the last quarter (net of cash and cash equivalents). - Current net debt stands at INR4,707 million. - Interest costs have decreased by 20% quarter-over-quarter due to better credit rating and access to economical funds. - The company aims to be net debt free within 2 to 3 years. - No specific mentions of new fundraising through debt or equity at present; focus is on maintaining healthy leverage and using internal and customer funds for growth investments.

- OneSource Specialty Pharma plans to invest over $100 million over the next couple of years to expand capacity and capabilities. - Capacity is being increased from a rated 40 million to over 90 million by December 2025. - Capacity additions are primarily in India, but the company is open to exploring expansion outside India, both organically and inorganically. - Customer participation in capex is part of arrangements to secure capacity (e.g., take-or-pay contracts, reservation fees). - The company is adding new capabilities, such as high-viscous pre-filled syringes, within its broader platform. - Investments also include integration programs, upgrading IT systems, and improving digitalization and quality standards. - The company targets debt reduction aligned with capex and has reduced net debt to INR4,707 million as of March 2025, aiming for net debt-free status in 2-3 years.

- OneSource Specialty Pharma aims for $400 million in sales revenue by FY 2028, maintaining 38%-40% EBITDA margin. - Strong order book supports significant capacity expansion from 40 million to over 90 million units by December 2025. - FY 2026 is a transition year with lumpy revenue due to regulatory approvals; stronger H2 expected, mirroring FY 2025 pattern. - Customer forecasts and patent expiries guide capacity ramp-up; near full utilization expected as commercial launches increase. - Anticipated launches of key products like Liraglutide, Teriparatide, and Semaglutide generics in FY 2026 across multiple markets. - Market expansion driven by increased access in underserved regions (e.g., Brazil and Canada), with 4-12x potential volume growth. - Investment of over $100 million underway for capacity and capability expansion to support future growth. - New therapies, especially injectables, expected to sustain demand; oral therapy share capped at ~25%.

- OneSource Specialty Pharma anticipates strong revenue growth, targeting $400 million by FY '28, with a 30% CAGR from FY '25 to '28. - EBITDA margins are expected to remain steady around 38% to 40%, demonstrating strong operating leverage. - FY '26 is seen as a transitional year with commercial launches ramping up in H2, leading to lumpy quarterly performance but a strong exit run rate. - Adjusted PAT improved significantly in FY '25, and EPS stands at INR21.4 for full year, with further growth expected as DDC projects move from milestone to commercial stages. - Long-term, the company aims to be net debt free in 2-3 years, strengthening financial health. - NBE (biologics) commercialization expected between FY '28 and '29, with limited near-term revenue impact. - Overall, strong order book and capacity expansions support confidence in achieving near-term growth and profitability targets.

- OneSource Specialty Pharma has a strong and growing order book with around 50 ongoing drug-device combination (DDC) projects, including both fully delivered and in-execution. - The order book is aligned with customers' forecasts and patent expiries over the next 2-3 years, supporting capacity ramp-up. - The company is actively adding capacity, aiming to nearly double rated capacity from about 40 million to over 90 million by the end of 2025. - Capacity expansions are primarily to serve ongoing Master Service Agreements (MSAs) and Customer-Specific Agreements (CSAs). - Customers have provided take-or-pay contracts and long-term forecasts, ensuring secured capacity allocations. - The robust order book underpins the company’s FY '28 guidance of $400 million in sales, supporting continued growth through FY '26 and into FY '27. - The broad and diverse customer base reduces dependency on any single approval or market.